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INTRODUCTION 
The most common infectious diseases are those involving the upper and lower 
respiratory tract. Their treatment are frequently difficult due different resistance mechanisms 
spreading among respiratory pathogens and leading to multi-resistant strains. 
 S. pneumoniae, the most common causative agent of community acquired 
pneumonia can be ranged in 90 different serotypes according to its polysaccharide capsule 
antigen. The mechanism of action of vaccines is based on the fact that antibodies produced 
against these antigens prevent invasive infections caused by the same serotype S. pneumoniae. 
Vaccines against severe S. pneumoniae infections were developed to cover the most prevalent 
serotypes. 
 Previously all S. pneumoniae strains were susceptible to penicillins. Penicillins act 
on penicillin binding proteins (PBPs) present in the cytoplasmic membrane of the bacteria and 
are involved in the peptidoglycan synthesis of the cell wall as transpeptidases and 
transglycolases. Penicillins irreversibly bind to the PBPs and inactivate them. The synthesis of 
the PBPs are coded by mosaic genes. Depending from the composition of these mosaic genes 
low-level or high-level penicillin resistance as well as amoxicillin and 3rd generation 
cephalosporine resistance can develop in pneumococci. Penicillin G is not the drug of first 
choice any more in S. pneumoniae infections, however the in vitro resistance against it indicate 
well the resistance of the strains to beta-lactam antibiotics. About 50% of the population 
harbour S. pneumoniae in the nasopharynx without any symptoms (carrier status). All virus 
infections promote the binding of bacteria to the epithelial cells of the respiratory tract. S. 
pneumoniae may spread from the nasopharynx and reach the lower respiratory tract causing 
inflammation. S. pneumoniae is still one of the most prevalent lower respiratory tract 
pathogens especially in the case of community acquired pneumonia. According to a 
surveillance data from the US, 50% of those died of severe S. pneumoniae infections could 
have been saved by the widespread vaccination against S. pneumoniae. Similar to other 
European countries Hungary has developed its own vaccination policy to prevent S. 
pneumoniae infections. 
 In ventilated and cystic fibrosis patients the biofilm formation plays important role 
in the pathogenesis of P. aeruginosa infections. Antibacterial agents can not cure these patients 
without the help of their own immune system. Bacteria living in biofilms are protected against 
antibacterials and sometimes even against phagocytes. According to this the decrease of the 
biofilm formation or destruction of the biofilm may help in the successful treatment of these 
patients. Certain macrolide antibiotics are proved to inhibit the alginate production of P. 
aeruginosa strains and therefore they are used as an adjuvants treatment in cystic fibrosis 
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patients. However, the treatment of infections caused by multi-resistant P. aeruginosa strains 
are often seemed as impossible. 
The most common Gram-negative bacteria causing nosocomial pneumonia are Klebsiella 
pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Serratia 
marcescens and Pseudomonas aeruginosa. As a result of misuse and overuse of beta-lactam 
antibacterials the beta-lactamase producing isolates and those producing extended spectrum 
beta-lactamases (ESBLs) can be isolated more and more frequently. The mortality rate of 
severe nosocomial pneumonia is between 50 and 100%, hence the prevalence and resistance 
patterns of pathogens should be monitored to be able to find optimal empiric therapy. 
 
 
AIMS  
Aims of this study were: 
1. To evaluate the penicillin, amoxicillin, ceftriaxone and macrolide resistance of 
clinical S. pneumoniae isolates obtained between 1997 and 2005. Analyses were 
performed according to age groups, specimen types and specimen origin (inpatient 
or outpatient). We collected data on the carriage of S. pneumoniae in children. We 
were also interested in whether the S. pneumoniae vaccines introduced in Hungary 
cover the frequently isolated serotypes. We also investigated the efficacy of a new 
3rd generation cephalosporin against high-level and low-level penicillin resistant S. 
pneumoniae isolates. 
2. To follow the respiratory tract colonisation of cystic fibrosis (CF) patients treated in 
a cystic fibrosis outpatients clinic between 1999 and 2001. We aimed to develop an 
in vitro method suitable to detect the biofilm production of P. aeruginosa strains 
isolated from these patients and to test the inhibitory effect of macrolides on biofilm 
formation by the new method. 
3. To compare and evaluate the clinical relevance of two lower respiratory tract 
sampling methods used in an Intensive Care Unit. The prevalence and ESBL 
production of Enterobacteriaceae strains isolated from patients with nosocomial 
pneumonia were also analysed. 
4. To investigate the synergistic effect of different antibiotic combinations and to 
select a time-saving method to help clinicians in the selection of effective antibiotic 
combinations against multi-resistant respiratory tract pathogens. 
5. To study the resistance mechanisms of common respiratory tract pathogens against 
beta-lactam antibiotics by conventional and molecular methods. 
 
5/16 
 
MATERIALS AND METHODS 
Bacterial strains 
Thirty-five S. pneumoniae isolates were obtained from the nasopharynx of healthy children 
(aged 3-6 years) attending day-care centres. 93 isolates were collected earlier in the Heim Pál 
Hospital, Budapest. All other S. pneumoniae isolates - involved in different studies - were 
isolated in the Institute of Clinical Microbiology, University of Szeged from the upper and 
lower respiratory tract, blood culture, and cerebrospinal fluid of symptomatic patients.  
The P. aeruginosa isolates (110) were recovered from the upper and lower respiratory 
tract of cystic fibrosis patients. The 179 K. pneumoniae, 82 E. cloacae, 7 E. coli and the 15 S. 
marcescens isolates were cultured mainly from the lower respiratory tract of different patients.  
Specimen collection 
The nasopharyngeal swabs were used for the surveillance study (S. pneumoniae carriage), 
sputum and throat samples were taken from cystic fibrosis patients. Sputum was cultured after 
cytological analysis (acceptable sample: >25 neutrophils and <10 epithelial cells/ field; 
examining at least 40 fields with 100x zoom). The endotracheal aspirates (EA) - obtained from 
ventilated patient - were examined microscopically to determine the presence or absence of 
neutrophil granulocytes. In the case of EA, the cut-off value was >105 colony forming unit/ml 
(CFU/ml), while in the case of protected bronchoalveolar lavage (miniBAL) it was >103 
CFU/ml. 
Serotyping of Streptococcus pneumoniae isolates 
Serotyping was performed with the S. pneumoniae typing antisera purchased from Mast Group 
Ltd (Bootle UK).  
Antimicrobial susceptibility testing 
Susceptibility testing was performed by the disk diffusion method. The minimum inhibitory 
concentration (MIC) was determined by Etest (AB Biodisk, Solna, Sweden), agar dilution or 
micro-broth dilution method. NCCLS/CLSI guidelines were used rigorously during the whole 
study.  
Investigation of beta-lactamase production and its genetic background  
Beta-lactamase production was detected by discs containing nitrocefin (Difco). The substrate 
profiles of the enzymes were determined by the micro-colorimetric method of Escamilla. For 
the enzyme induction experiments the disc diffusion method was used. The inducer antibiotics 
were cefoxitin and imipenem whereas the indicator antibiotics were cefuroxime, cefoperazone, 
cefotaxime and ceftazidime. For the screening of ESBL production the double-disc method 
(ceftazidime and amoxicillin/clavulanic acid), the five-disc method of Jarlier (ceftazidime, 
cefotaxime, aztreonam, cefepim and amoxicillin/clavulanic acid) or the Etest methodology was 
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applied. For the molecular investigation of ESBL production of K pneumoniae, E. cloaceae 
and S. marcescens strains the plasmid DNA was isolated by the magic Miniprep DNA 
Purification Kit (Promega Madison WI). Plasmids were detected in 0.7% agarose gel, stained 
with ethidium bromide. Specific primers for the TEM and SHV genes were used for the 
amplification. Single-stranded conformation polymorphism (SSCP) analysis was performed to 
differentiate different types of SHV genes after digestion by PstI enzyme. The fragments of the 
ssDNA were visualised by silver nitrate staining. 
Examination of synergisms  
To evaluate the combined effect of beta-lactamase inhibitors (clavulanic acid, sulbactam) and 
cefoperazone, the chequerboard titration (according to Lorian) and the killing curve method 
were used. The initial inoculum was 105 CFU/ml. The effect of cefoperazone alone (at 1xMIC 
or 2xMIC concentrations) or combined with 1 mg/l clavulanic acid and 1mg/l or 16 mg/l 
sulbactam was evaluated by killing curve method. The cultures were incubated at 37oC in 
normal atmosphere. The CFU counts were determined after incubation for 6 and 24 hours. The 
Fractional Inhibitory Concentration (FIC) index was calculated to classify the combined effect. 
The applicability of the Etest method in synergism studies was also evaluated. 
Examination of biofilm production 
The biofilm production of mucoid P. aeruginosa strains isolated from the respiratory tract 
specimens of cystic fibrosis patients was investigated in vitro by the Enzym-Linked 
Lectinsorbent Assay (ELLA) according to Leriche. After standardisation of the method we 
investigated the inhibition effect of clarithromycin on biofilm production (on those strains 
which proved to be good biofilm producers). In this experiment the method of Leriche was 
changed as clarithromycin (to produce a solution with 50, 100, 200, 300, and 400 mg/l final 
clarithromycin concentrations) was solved in the culture medium. After the daily washing 
procedures with the clarithromycin buffer we added peroxidase conjugated lectin and 
compared the inhibitory effect of clarithromycin to control cultures. 
Direct Etest examination of sputum 
After cytological examination and mucolysis, 100 µl of the sputum of cystic fibrosis patients 
were plated on blood agar. Etest strips containing antipseudomonal drugs were placed on the 
culture plates and incubated for 18-24 hours at 37 oC in normal athmosphere. We determined 
the MICs of different P. aeruginosa strains, revealed the presence of multiresistant strains and 
examined the susceptibility of the normal flora to the corresponding antibiotics. 
Antibiotic consumption 
The annual wholesaler data on the community pharmacy sales of antibacterials were collected 
retrospectively for the 8-year period 1998-2005. Products were classified and calculations were 
performed according to the 2005 version of the World Health Organization ATC (Anatomical - 
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Therapeutic - Chemical) DDD (Defined Daily Dose) index. For investigating the effect of 
antibiotic consumption on penicillin and macrolide resistance of S. pneumoniae, only the oral 
formulations were included in the analyses (beta-lactam antibacterials [ATC code: J01C] and 
the macrolides, lincosamides [J01F]). The nationwide antibiotic consumption and that of 
Csongrád County were expressed as DDD per 1000 inhabitant-days. 
Statistical analysis 
All resistance data were collected retrospectively from our laboratory database. Repeat isolates 
from individual patients were excluded. Differences in the distribution of resistance patterns 
were analysed by means of chi-square test and Fisher's exact test, as appropriate, using the 
SPSS program package (version 13.0). A P value of <0.05 was considered to be statistically 
significant. 
 
 
RESULTS  
1. Results obtained during investigations of S. pneumoniae isolates 
 Due to controversial data published in the ‘90s about the penicillin resistance of S. 
pneumoniae isolates in Hungary, a retrospective evaluation of penicillin, amoxicillin, 
ceftriaxone and macrolide resistance of S. pneumoniae isolates was carried out. All clinical 
isolates between 1998 and 2005 were retrieved from the database of our institute. During this 
period the resistance determination methods suggested by NCCLS/CLSI were used rigorously. 
Until 2002 our data showed a much lower prevalence of high-level penicillin resistant S. 
pneumoniae isolates compared to those published by other authors and could be found in 
national databases. These discrepancies might be due to the usage of different, not standardised 
methods in the screening and confirmation of high-level penicillin resistant pneumococci in 
many Hungarian laboratories.  
 During this 8-year period both inpatient and outpatient samples were included, but 
the proportion of the patients and hence the number of the isolates in these two groups had 
changed over time. Between 1998 and 2001 (Period I) our laboratory provided a service almost 
exclusively for the different clinical wards and for their outpatient departments, while from 
2002 (Period II) increased number of samples were sent by general practitioners and from the 
recently merged general paediatric hospital. These changes resulted in an increase in the total 
number of S. pneumoniae strains isolated from outpatients, especially from children. During 
the 8-year period 2670 S. pneumoniae strains were isolated from different samples. 1267 
strains were derived from inpatients, great majority (983 strains) from children (age: <14 
years). The frequency distribution of strains with high-level or low-level penicillin resistance 
varied considerably between the two periods. The prevalence rate of high-level penicillin-
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resistant S. pneumoniae strains decreased from Period I to Period II, despite of the same 
detection methodologies that were used. Among the 0-2 year old children, both in inpatients 
and outpatients, the prevalence rates of high-level penicillin-resistant S. pneumoniae strains 
were considerably lower in Period II compared to Period I (20% vs. 4% and 21% vs. 2%, 
respectively). A similar trend was seen among the strains isolated from 3-14 year old patients. 
Among the isolates obtained from adults (>14 years), the prevalence rate of high-level 
penicillin-resistant strains were low in both periods (8.7% vs. 2.5%). The amoxicillin and 
ceftriaxone resistance was rare during the whole study. The erythromycin and clindamycin 
resistance of the isolated strains were continuously and uniformly high.  
The national penicillin (J01C) consumption remained relatively stable between 
1998 and 2005 (mean ± SD: 8.45±0.51 DDD per 1000 inhabitant-days), with a transient peak 
in 1999, possibly in consequence of an influenza outbreak with concomitant bacterial 
infections. The consumption of penicillins with extended spectrum (J01CA) gradually 
decreased, while the usage of penicillins combined with beta-lactamase inhibitors (J01CR) 
continuously increased.  The consumption of the J01C, J01CA and J01CR subgroups in 
Csongrád County exhibited similar trends and were consequently slightly higher compared to 
national values. The consumption of macrolides and lincosamides (J01F) rose in Hungary 
through the years, as well as in Csongrád County. The antibiotic consumption and the 
prevalence rate of penicillin resistant S. pneumoniae strains are not associated. 
 Sero-types of 57 randomly selected S. pneumoniae isolates were determined. The 
sero-types of the strains recovered from 0-2 year old children were identical in 95% with those 
present in the conjugated pneumococcus vaccine used for the immunisation of this population. 
The isolates obtained from children above 2 years of age showed identity in 97% with the the 
serotypes of the corresponding vaccine. 
We also collected nasopharyngeal samples from 195 healthy children attending 4 
different day-care centres (two situated in the centre of the city and two situated outside of the 
city). Thirty three percent of them were S. pneumoniae carrier. An interesting observation is 
that children attending day-care centres in the city centre harboured S. pneumoniae only in 
11%, whereas in those attending suburban day-care centres the carriage rate was 29%. Of the 
35 strains, only one had an MIC of 4 mg/L for penicillin and an MIC of 1 mg/L for 
amoxicillin. An additional 13 strains had an MIC for penicillin between 0.125 and 1 mg/L, 
corresponding low-level penicillin resistance. Penicillin resistance was more frequent among 
children attending day-care centres in the city centre, presumably due to more frequent 
antibiotic use. None of the S. pneumoniae strains were resistant to ceftriaxone. Fourteen strains 
were resistant to erythromycin and clindamycin as well. 
9/16 
We also investigated the in vitro activity of cefditoren-pivoxil, a new 3rd generation 
cephalosporine against 35 isolates obtained from adult patients with pneumonia and against 93 
S. pneumoniae strains recovered from children with upper respiratory tract infection. In this 
later group the prevalence rates of high-level and low-level penicillin resistant S. pneumoniae 
strains were very high (54% and 22%, respectively). The MIC values for cefditoren-pivoxil 
were much lower than the average serum levels obtainable with the regular doses. According to 
these, cefditoren-pivoxil could be a useful alternative in the treatment of infections caused by 
high-level or low-level penicillin resistant strains. 
 
2. Results obtained during the investigation of P aeruginosa strains isolated from samples 
of cystic fibrosis patients. 
Twenty four patients - treated in a special CF outpatient clinic in Szeged - were 
monitored between July 1999 and June 2001. The upper and lower respiratory tract samples 
were cultured to detect the appearance or continuous presence of potential respiratory tract 
pathogens. During this period P. aeruginosa was isolated most frequently. In 1999 38%, in 
2000 33% and in 2001 36% of the patients were colonised with P. aeruginosa. This means that 
there was a permanent risk for colonisation and infection caused by P. aeruginosa.  
An in vitro model was developed to detect the biofilm formation of P. aeruginosa 
isolates. Mucoid colonies - isolated from cystic fibrosis patients - were selected for these 
experiments. To standardise the method we determined the optimal duration of the biofilm 
formation, the culture conditions and the signal system. In this model it was possible to 
measure and quantify the biofilm formation inhibition effect of clarithromycin. During the 
selection of proper drugs to treat already colonised cystic fibrosis patients, it is mandatory to 
differentiate various P. aeruginosa isolates with different resistance patterns. A new culture 
technique and a direct antibiotic resistance determination method were introduced. We applied 
this method to the lower respiratory tract specimens of symptomatic cystic fibrosis patients in 
order to determine the most suitable antibiotic treatment to kill mucoid P. aeruginosa and to 
save the normal respiratory tract flora. This method was also suitable for the direct 
differentiation of colonising bacteria with diverse antibiotic resistance patterns. 
 
3. Prevalence of the ESBL producing Enterobacteriacae strains isolated from the lower 
respiratory specimens of different patients.  
We evaluated the clinical relevance of culture results obtained by different lower respiratory 
tract sampling methods. We confirmed the advantages of protected bronchoalveolar lavage 
(miniBAL) over the tracheal aspirates. The culture results of lower respiratory tract specimens 
obtained between July 1997 and October 1999 by the miniBAL method and by tracheal 
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aspirates were compared. During this period 63 patients had hospital acquired pneumonia. Out 
of the 95 miniBAL samples 49 were positive and overall 66 pathogens were isolated. When the 
culture results of the tracheal aspirates were compared to those obtained by the miniBAL 
identical species isolation was found only in 66%. We can conclude that the invasive sampling 
method (miniBAL) can not be replaced by the tracheal aspirate in case of the intubated patients 
with hospital acquired pneumonia as prolonged hospital stay may result in colonisation of the 
upper respiratory tract with bacteria and may lead to false isolation results with tracheal 
aspirates.  
Between 2002 and 2005 the resistance patterns of Gram-negative pathogens isolated 
from the lower respiratoty tract of patients with nosocomial pneumonia were evaluated with 
special emphasis on resistance to beta-lactam antibiotics. The extended spectrum beta-
lactamase (ESBL) production was tested by different detection methods. The number of the 
ESBL producing Gram-negative strains did not differ significantly during the study period, and 
no dominant ESBL producing strain was found. 
 
4. Investigation of antibiotic synergisms in the case of Gram-negative respiratory tract 
pathogens. 
During the routine in vitro testing of antibiotic resistance by disc diffusion method a 
synergistic effect was observed between cefoperazone and amoxicillin/clavulanic acid. For 
further investigation of this phenomenon chequerboard titration and killing curve methods 
were used to investigate the combined effect of cefoperazone-clavulanic acid as well as 
cefoperazone-sulbactam combinations against 7 E. coli and 9 K. pneumoniae strains producing 
different types of  beta-lactamases (TEM and SHV). The effect of the cefoperazone/clavulanic 
acid combination was superior to that of cefoperazone/sulbactam, so this could be a suitable 
combination in the treatment of infections caused by beta-lactamase (TEM or SHV-type) 
producing Gram-negative bacteria. 
110 clinical P. aeruginosa isolates were evaluated by the Etest methodology to find 
effective antibiotic combinations. Thirty isolates proved to be ciprofloxacin resistant of which 
26 were multi-resistant (resistant to >3 drugs with antipseudomonal activity). According to the 
FIC index the ceftazidime/ciprofloxacin and piperacillin/amikacin combinations were 
synergistic against 10 strains, while the piperacillin/ciprofloxacin combination was synergistic 
against 7 strains.  In case of ciprofloxacin-intermediate resistant or ciprofloxacin susceptible 
strains these synergistic effects were less frequently found. Our results show that Etests are 
very practical for routine everyday use as rapid in vitro data can guide the clinicans to find 
effective antibiotic combinations for the treatment of infections. 
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5. Investigation of resistance mechanisms of beta-lactam-resistant Gram-negative 
bacteria belonging to the Enterobacteriaceae group 
 Clinical isolates of K. pneumoniae (170), E. cloaceae (82) and S. marcescens (15) 
were investigated for the beta-lactamase production. Out of the 267 isolates 109 (41%) 
harboured one or more beta-lactamase genes. The most prevalent ESBL-types among the K. 
pneumoniae strains were SHV-2 and SHV-5, whereas among the E. cloaceae strains the 
inducible Class C beta-lactamase was detected in 55%. The S. marcescens strains - isolated 
from a nosocomial epidemy (12 clinical and 3 environmental isolates) - were investigated by 
molecular methods. The PCR-SSCP analysis suggested that 14 S. marcescens strains not only 
produced the Class C, inducible chromosomal beta-lactamase, but also acquired a plasmid-
mediated SHV-2 type ESBL. The in vivo transfer of SHV-2 gene was assumed from an SHV-2 
positive K. pneumoniae strain present simultaneously in the same patient. In the hospital 
environment, mostly in the case of respiratory tract infections, we have to take into 
consideration the accumulation of multiple resistance mechanisms coded by chromosomal or  
plasmid genes and the inter-species gene transfer. 
 
 
CONCLUSIONS 
S. pneumoniae, the most frequent causative agent of community acquired 
pneumonia and upper respiratory tract infections may have severe, life-threatening 
consequences. Our retrospective evaluation of penicillin, amoxicillin, ceftriaxone, and 
macrolide resistance of S. pneumoniae strains showed that the prevalence of high-level 
penicillin resistant strains was very low (5.58%) especially in adult patients (4%) and among 
invasive isolates (3.8%). Low-level penicillin resistance were 37% and 39% in the isolates 
obtained from inpatients and outpatients. Throughout this 8-year period we rigorously used 
internationally accepted methodologies for the screening and confirmation of resistances. 
These data differ greatly from those reported previously in Hungary. Resistance to amoxicillin 
(that is extensively used for the treatment of S. pneumoniae infections) and to ceftriaxone (that 
is used for the treatment of severe invasive infections) were 2.62% and 1.12, respectively. 
However the macrolide resistance was continuously high during the study period, which means 
that macrolides can not be used for the empiric treatment of S. pneumoniae infections.  
The carriage rate of S. pneumoniae in children attending day-care centres was 33%. 
Resistance to penicillin, amoxicillin, ceftriaxone and macrolides was similar to that found 
among clinical isolates. 
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The investigation of the serotypes of randomly selected clinical S. pneumoniae 
isolates showed that 95% and 97 % of the serotypes were covered by the respective vaccines 
used for the immunisations. According to this, immunisation programmes may prevent severe 
consequences of S. pneumoniae infections in Hungary. 
Our study shows that the new 3rd generation cephalosporine, cefditoren-pivoxil is 
very active against both high-level and low-level penicillin resistant S. pneumoniae strains. The 
MIC values of cefditoren-pivoxil were much lower than the average serum levels obtainable 
with the regular doses. According to these cefditoren-pivoxil could be a useful alternative for 
the treatment of infections caused by high-level or low-level penicillin resistant strains. 
With the development of an in vitro method we were able to detect the biofilm 
formation of P. aeruginosa strains that are frequently colonising the airways of cystic fibrosis 
patients. With this method we could provide useful information about the inhibitory effect of 
macrolides (clarythromycin) on biofilm formation. By using the direct antibiotic resistance 
detection method - carried out with Etests - we can help to find the most appropriate antibiotics 
that are able to kill the simultaneously detected pathogen colonies and strains with diverse 
antibiotic resistance patterns while preserving the normal flora.  
Gram-negative bacteria belonging to the Enterobacteriaceae group are the most 
common pathogens of ventilator-associated pneumonia acquired in intensive care units. To get 
clinically relevant culture results, the usage of miniBAL instead of tracheal aspirate is 
recommended in case of intubated patients. Screening the ESBL production of respiratory tract 
pathogens helps to select effective empiric therapy for these patients. The appearance of ESBL 
producing strains urge the restrictive use of certain beta-lactam antibiotics. As ESBL producing 
Gram-negative bacteria were rarely isolated in our intensive care units it can be regarded as a 
success. 
In vitro methods are available to investigate the synergistic effect of antibiotic 
combinations. We confirmed that synergistic effect of cefoperazone and clavulanic acid against 
beta-lactamase producing Gram-negative bacteria is superior to the cefoperazone-sulbactam 
combination. The chequerboard titration and the killing curve method used for these 
examinations are time- and labour-consuming methods. A more suitable method for the every 
day routine, the Etest methodology was evaluated and compared to the classical methods.  The 
synergistic effect of different antipseudomonal antibitotic-ciprofloxacin combinations were 
proved by this method even in case of multi-resistant P. aeruginosa strains. The efficacy of the 
combinations (FIC index) was highly dependent on the isolate, on the level of the resistance 
and on the combined antibiotics. Individual testing is necessary to guide therapy caused by 
multi-resistant strains. 
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To investigate the genetic background of beta-lactam resistance is extremely 
important as beta-lactamase genes present on plasmids may easily spread in the hospital 
environment. On the other hand chromosomal genes as well as plasmid genes mutate according 
to the antibiotics used in the wards. Our data confirm the widespread presence of TEM and 
SHV genes among clinical Gram-negative isolates. The high co-prevalence of the inducible 
chromosomal and stable derepressed beta-lactamase genes in E. cloaceae was also confirmed. 
In a nosocomial epidemy the in vivo transfer of SHV-2 gene was assumed from an SHV-2 
positive K. pneumoniae strain into a S. marcescens strain producing a Class C beta-lactamase. 
The presence of both strains could be confirmed in the same ward, in the same patient and at 
the same time. 
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